Sun Pharma receives nod to sell Cymbalta copy
Sun Pharma can sell the capsules for 180 days without competition from rival generic drug makers
Mumbai: Sun Pharmaceutical Industries Ltd, India’s most valuable drug maker, on Thursday said it has received approval from the US Food and Drug Administration (FDA) to sell a copy of drug maker Eli Lilly and Co.’s Cymbalta capsules that is used for the treatment of depression and anxiety disorders.
Sun Pharma can sell the capsules for 180 days without competition from rival generic drug makers as it was the first company to file an abbreviated new drug application (ANDA) for the drug.
These capsules have annual sales of approximately $5.5 billion in the US, the statement said.
Shares of Sun Pharma dropped 1.47% to close at ₹ 575.35 on the BSE on Thursday, while the exchange’s benchmark Sensex lost 1.16% to 20,925.61 points.
Catch all the Industry News, Banking News and Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
MoreLess
First Published:12 Dec 2013, 05:02 PM IST
- Top Gainers
- Top Losers
- 52 Week High